Suivant

Lecture automatique

PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat

10 Vues • 07/08/23
Partager
Intégrer
administrator
administrator
Les abonnés
0

UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat

Montre plus
0 commentaires sort Trier par
Commentaires de Facebook

Suivant

Lecture automatique